Sign up USA
Proactive Investors - Run By Investors For Investors

QLT receives two fast track designations for degenerative eye disease drug

QLT receives two fast track designations for degenerative eye disease drug

QLT (TSE:QLT) (NASDAQ:QLTI) announced Wednesday it received two fast track designations from the U.S. FDA for the speedy development of its QLT091001 drug, intended for the treatment of two degenerative eye diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

Both LCA and RP are inherited genetic diseases, frequently caused by mutations to the LRAT and RPE65 genes. QTL's OTL091001 drug is an oral synthetic retinoid, and works by replacing the 11-cis-retinal chromophore, an essential part of visual function.

The FDA's fast track designation facilitates the quick development of investigational drugs that show promise in treating serious diseases, expediting the regulatory review process to fulfill a previously unmet medical need.

In May, QLT released the results of its phase 1b study of QLT091001 in the treatment of LCA. The results of the 12-patient clinical trial reported that eight subjects showed significant improvements in the study's endpoints - visual acuity and visual fields.

The company said it is continuing to follow up with the 12 patients from its phase 1b study, and intends to complete subject enrollment for the RP-based study by the end of the year.

"QLT091001's Fast Track designation, along with its orphan drug designation, highlights the need for therapeutic options for those patients suffering from inherited retinal diseases," said president and CEO, Bob Butchofsky.

"We are pleased that the FDA recognizes QLT091001 as a potential treatment for LCA and RP and we are now working diligently to advance the development of this compound under the Fast Track process."

Characterized by abnormalities like roving eye movements and sensitivity to light, and manifested in severe vision loss beginning at birth, LCA affects an estimated one infant out of every 81,000 births.

Meanwhile, RP is characterized by the degeneration of photoreceptors in the eye, and affects at least 300,000 people across the globe.

Based in Vancouver, B.C., ocular-focused medical company QLT's stock closed on Tuesday at $7.20 per share.

View full QLT profile View Profile

QLT Inc. Timeline

December 06 2012

Related Articles

January 08 2018
The device can now be sold to aid in heart treatment throughout the European Union
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
Frosties Box
December 04 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use